Lifestream cholesterol test
This article was originally published in The Tan Sheet
Executive Summary
Lifestream Technologies receives FDA 510k clearance to market consumer cholesterol test incorporating Health Risk Assessment technology, enabling users to track cholesterol levels as well as personal risk of heart attack and obesity. Users can obtain a Health Risk Assessment profile after taking a three-minute cholesterol test and entering additional risk factors, including diabetic status, systolic and diastolic blood pressure and HDL-C break-out from a recent lipid profile. The test will be available to consumers through the firm's 1website in late June and move to other distribution channels later this year. McNeil recently announced a licensing agreement with International Medical Innovations to develop and market the PREVU(x) consumer cholesterol test (2"The Tan Sheet" June 7, 2004, p. 10)...
You may also be interested in...
McNeil Reaches Consumer Cholesterol Testing Licensing Deal With IMI
McNeil Consumer Health is seeking to leverage the potential Rx-to-OTC switch of J&J/Merck's Mevacor (lovastatin) with an agreement to license International Medical Innovations' predictive tests for coronary artery disease (CAD)
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.